Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Clinical trial NCT02780609 · COMPLETED
Trial details
- NCT number
- NCT02780609
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-20
- Primary completion
- 2021-02-20
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.